Immunotherapy, a rapidly evolving field in cancer treatment, capitalizes on the body's innate immune system to combat malignancies. It has revolutionized the medical landscape, offering new hope to patients with various types of cancers. This article aims to provide a comprehensive understanding of the fundamental principles of immunotherapy.
Immunotherapy works by stimulating or restoring the immune system's ability to fight off cancer. It uses substances produced by the body or in a laboratory to bolster or manipulate immune responses. The two main types of immunotherapy include active and passive. Active immunotherapy stimulates the immune system to attack cancer cells, while passive immunotherapy involves the administration of immune components, such as antibodies.
Immunotherapy encompasses a broad range of treatments including monoclonal antibodies, immune checkpoint inhibitors, cancer vaccines, and adoptive cell therapy. Monoclonal antibodies are laboratory-produced molecules engineered to serve as substitute antibodies that can restore, enhance or mimic the immune system's attack on cancer cells. Immune checkpoint inhibitors block immune checkpoints, enhancing immune responses against cancer cells. Cancer vaccines are substances introduced into the body to provoke an immune response against certain diseases. Adoptive cell therapy involves the modification of a patient's T cells to enhance their ability to fight cancer.
Despite the significant advances in immunotherapy, challenges persist. These include side effects, the unpredictability of responses, and the high cost of treatment. Future research is focusing on identifying biomarkers to predict response, refining treatment combinations, and minimizing toxicity.
Immunotherapy represents a paradigm shift in cancer treatment. While challenges exist, its potential to offer a therapeutic advantage over traditional treatments is significant. As research continues to unravel the complexities of the immune system, we can anticipate further advancements in this promising field.
1.
Stem Cell Selection Unneeded for SSc Transplant Therapy?
2.
Radiation from CT scans could account for 5% of all cancer cases a year, study suggests
3.
Do I have prostate cancer? Why a simple PSA blood test alone won't give you the answer
4.
In Hemophilia A and B, a Novel Monoclonal Antibody Reduces Bleeding.
5.
Tumor infiltration of major blood vessels, not metastasis, may be primary cause of cancer death
1.
Revolutionizing Oncology Trials: Optimization, Matching, Diversity, and Decentralization
2.
Emerging Dysregulated Signaling Pathways in Early-Onset Colorectal Cancer
3.
Exploring the Use of Bevacizumab in Treating Different Types of Cancers
4.
A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities
5.
Unlocking the Secrets of Squamous Cell Carcinoma: New Hope for Patients
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
2.
The Era of Targeted Therapies for ALK+ NSCLC: A Paradigm Shift
3.
A New Era in Managing Cancer-Associated Thrombosis
4.
Navigating the Complexities of Ph Negative ALL - Part IX
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VIII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation